Join Growin Stock Community!

Veru inc.VERU.US Overview

US StockHealthcare
(No presentation for VERU)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

VERU AI Insights

VERU Overall Performance

VERU AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VERU Recent Performance

-2.13%

Veru inc.

0.05%

Avg of Sector

-0.31%

S&P500

VERU PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

VERU Key Information

VERU Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

VERU Profile

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Price of VERU

VERU FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VERU Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.79
PB Ratio
1.15
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
40.37%
Net Margin
-491.40%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.79
PB Ratio
1.15
Price-to-FCF
-
Gross Margin
40.37%
Net Margin
-491.40%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is VERU's latest earnings report released?

    The most recent financial report for Veru inc. (VERU) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VERU's short-term business performance and financial health. For the latest updates on VERU's earnings releases, visit this page regularly.

  • How much debt does VERU have?

    As of the end of the reporting period, Veru inc. (VERU) had total debt of 2.98M, with a debt ratio of 0.06. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does VERU have?

    At the end of the period, Veru inc. (VERU) held Total Cash and Cash Equivalents of 32.99M, accounting for 0.69 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is VERU's EPS continuing to grow?

    According to the past four quarterly reports, Veru inc. (VERU)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.26. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VERU?

    Veru inc. (VERU)'s Free Cash Flow (FCF) for the period is -6.17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 45.57% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of VERU?

    The latest valuation data shows Veru inc. (VERU) has a Price-To-Earnings (PE) ratio of -1.93 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.